Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | CTRC | Q99895 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12948196 | 0.77 | GABRA1 (0.34) | GABRA1GABRB2 | |
| SCHEMBL12168967 | 0.75 | KDM4E (0.38) | KDM4EMAPK1 | |
| SCHEMBL28594543 | 0.75 | GABRA1 (0.48) | KDM4EMAPK1GABRA1GABRB2CTRC | |
| SCHEMBL16382260 | 0.72 | KDM4E (0.54) | KDM4EMAPK1GABRA1GABRB2CTRC | |
| SCHEMBL12188715 | 0.72 | KDM4E (0.39) | KDM4EMAPK1GABRA1GABRB2CTRC | |
| SCHEMBL19940597 | 0.69 | GABRA1 (0.56) | GABRA1GABRB2 | |
| SCHEMBL15782818 | 0.67 | CA12 (0.47) | KDM4EMAPK1 | |
| SCHEMBL9495647 | 0.66 | HSD17B10 (0.33) | GABRA1GABRB2CTRC | |
| SCHEMBL981305 | 0.66 | — | — | |
| SCHEMBL12596204 | 0.65 | NPC1 (0.33) | MAPK1GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | PDE12, PDE7A, PDE10A | KDM4E 1865/4885MAPK1 1096/4885GABRA1 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.